Global Financial Private Client’s Vertex Pharmaceuticals VRTX Stock Holding History

Global Financial Private Client’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-174	Closed	-$84.4K	–	1563
2025 Q1	$84.4K	Buy	174 +7	+4%	+$3.26K	0.03%	280
2024 Q4	$67.3K	Buy	167 +1	+0.6%	+$464	0.03%	300
2024 Q3	$77.2K	Buy	166 +20	+14%	+$9.61K	0.03%	287
2024 Q2	$68.4K	Hold	146	–	–	0.03%	274
2024 Q1	$61.4K	Buy	146 +2	+1%	+$845	0.03%	287
2023 Q4	$58.6K	Hold	144	–	–	0.03%	283
2023 Q3	$50.1K	Hold	144	–	–	0.03%	287
2023 Q2	$50K	Hold	144	–	–	0.02%	290
2023 Q1	$45.6K	Hold	144	–	–	0.02%	290
2022 Q4	$41.6K	Hold	144	–	–	0.02%	292
2022 Q3	$42.8K	Hold	144	–	–	0.02%	285
2022 Q2	$41.4K	Hold	144	–	–	0.02%	276
2022 Q1	$38.3K	Hold	144	–	–	0.02%	292
2021 Q4	$31.6K	Hold	144	–	–	0.02%	307
2021 Q3	$26K	Hold	144	–	–	0.01%	290
2021 Q2	$29.1K	Hold	144	–	–	0.02%	291
2021 Q1	$30.7K	Hold	144	–	–	0.02%	249
2020 Q4	$34K	Buy	144 +4	+3%	+$918	0.03%	224
2020 Q3	$38.3K	Hold	140	–	–	0.03%	210
2020 Q2	$40.1K	Hold	140	–	–	0.03%	234
2020 Q1	$31.6K	Hold	140	–	–	0.03%	260
2019 Q4	$30.7K	Buy	+140	New	+$28.3K	0.03%	295

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Global Financial Private Client's VRTX Position: Q2 2025 in Review

Global Financial Private Client sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 174 shares — an estimated $84.4K sold.

Global Financial Private Client first reported a position in VRTX in Q4 2019 and held it in 22 quarters. The position peaked at $84.4K in Q1 2025. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

Global Financial Private Client reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Global Financial Private Client sold 174 Vertex Pharmaceuticals shares in Q2 2025, an estimated $84.4K.
Global Financial Private Client first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 22 quarters.
Global Financial Private Client's Vertex Pharmaceuticals position peaked at $84.4K in Q1 2025.
1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Global Financial Private Client's 13F filing for Q2 2025, filed 10 Jul 2025.